These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 18430132)

  • 1. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing strategies for the management of invasive fungal infections.
    Rapp RP
    Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of mycoses in surgical patients -- review of the literature.
    Holzheimer RG; Dralle H
    Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guideline based treatment of invasive aspergillosis].
    Karthaus M
    Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of amphotericin B in the treatment of invasive fungal infections.
    Klepser M
    J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on antifungal treatment of invasive Candida and Aspergillus infections.
    Maschmeyer G; Ruhnke M
    Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current role of amphotericin B lipid complex in managing systemic fungal infections.
    Chu P; Sadullah S
    Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
    Matsue K; Uryu H; Koseki M; Asada N; Takeuchi M
    Clin Infect Dis; 2006 Mar; 42(6):753-7. PubMed ID: 16477548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fungal infections in cancer patients: an escalating problem.
    Samonis G; Bafaloukos D
    In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
    Cornely OA
    Infection; 2008 Aug; 36(4):296-313. PubMed ID: 18642109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing strategies for treatment of systemic mycoses.
    Graybill JR
    Braz J Infect Dis; 2000 Apr; 4(2):47-54. PubMed ID: 11012295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.